Three poster presentations will be given by the company and its collaborators Florence Atrafi, MD, a clinical investigator on the phase 1 NAPOLY study, has received a prestigious ASCO Merit Award in recognition of her abstract that highlights important research findings Maastricht, The Netherlands, 17 May 2019 – Cristal Therapeutics, a clinical-stage pharmaceutical company developing […]
EACR: Nanotechnology in Cancer
September 12-14 EACR: Nanotechnology in Cancer Cambridge, UK
Nordic Life Sciences
September 10-12 Nordic Life Sciences Malmö, Sweden
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
Maastricht, The Netherlands, 1stAugust 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman. Dr Cautreels succeeds Simon Sturge, who steps down […]
CRS
July 21–24 CRS Valencia, Spain
GapSummit
June 16-19 GapSummit Boston, USA
BIO2019
June 3-6 BIO2019 Philadelphia, USA
ASCO
May 31 – June 4 ASCO Chicago, USA
CIMT Annual Meeting
May 21-23 CIMT 2019 Annual Meeting Mainz, Germany
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors
Three poster presentations will be given by the company and its collaborators Florence Atrafi, MD, a clinical investigator on the phase 1 NAPOLY study, has received a prestigious ASCO Merit Award in recognition of her abstract that highlights important research findings Maastricht, The Netherlands, 17 May 2019 – Cristal Therapeutics, a clinical-stage pharmaceutical company developing […]
Knowledge for Growth
May 9 Knowledge for Growth Ghent, Belgium